其 他 安 全 警 示
|
| |
| The United States: FDA issues class-wide labeling changes for testosterone products (English only) |
| |
The United States Food and Drug Administration (FDA) announces that FDA informed sponsors of testosterone products about new labeling changes following the agency’s review of the findings from the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) clinical trial and the results from required postmarket ambulatory blood pressure (ABPM) studies.
Led by the TRAVERSE trial’s results, FDA is recommending changes to current labeling language, to include:
• adding the results of the TRAVERSE trial to all testosterone products;
• retaining “Limitation of Use” language for age-related hypogonadism; and
• removing language from the Boxed Warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products.
Led by results of the ABPM studies, FDA is also requiring changes to current labeling language, to include:
• adding product-specific information on increased blood pressure for testosterone products with completed ABPM studies;
• adding a new warning about increased blood pressure for testosterone products which currently do not have such a warning in their labeling.
Testosterone, a hormone essential to the development of male growth and masculine characteristics, is used in men who lack or have low testosterone levels in conjunction with an associated medical condition. Current FDA-approved testosterone formulations include oral, topical gel, transdermal patch, buccal system (applied to upper gum or inner cheek), and injection.
FDA first convened a Joint Meeting of the Bone, Reproductive and Urologic Drugs and the Drug Safety and Risk Management Advisory Committee in September 2014 following increased reports of stroke, heart attack, and death in men taking FDA-approved testosterone products. This meeting resulted in the agency’s recommendation for an industry-wide clinical trial to assess the safety of use in men with age-related hypogonadism (insufficient sex hormone production). Results from the TRAVERSE trial were submitted in 2023, concluding that there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.
Additionally, in 2016 and 2017, FDA recommended ABPM studies as part of the premarket development of two different testosterone products, administered by two different routes (subcutaneous injection and oral). Consistent results from the premarket ABPM studies of the two products raised concerns that use of testosterone products could lead to increased blood pressure. In March 2018, FDA also issued a postmarket requirement that individual ABPM studies be conducted for all testosterone products. Results from the completed ABPM studies confirmed an increase in blood pressure with use of all testosterone products, class-wide.
The action in this announcement follows several prior FDA actions regarding the safety of testosterone products, including a January 2014 Drug Safety Communication (DSC) warning of reported risks of stroke, heart attack, and death in men taking FDA-approved testosterone products; and a March 2015 DSC informing of required labeling changes and urging caution when using testosterone products for low testosterone due to aging.
Please refer to the following website in FDA for details:
http://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products
In Hong Kong, there are 7 registered pharmaceutical products containing testosterone. All products are prescription-only medicines. So far, with regard to testosterone, the Department of Health (DH) has received 1 case of adverse drug reaction which was not related to increased blood pressure. Related news on cardiovascular risk was previously issued by various overseas drug regulatory authorities, and was posted on the Drug Office website since 4 February 2014, with the latest update posted on 31 December 2016. Letters to inform local healthcare professionals were issued on 16 July 2014 and 13 October 2014.
In February 2015, the Registration Committee of the Pharmacy and Poisons Board discussed the matter, and decided that the package insert of products containing testosterone should include safety information on the cardiovascular risk, including the risk of increased blood pressure. The DH will remain vigilant on safety update of the drug issued by other overseas drug regulatory authorities.
Ends/Saturday, Mar 1, 2025
Issued at HKT 12:45
|
| |
|
